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50 years old is rare, and when it does occur 
it usually points to a predisposing factor, as 
in this case, where a brain metastasis led to 
the formation of a hematoma (Gelabert-
González et al., 2012).
Moreover, while the radiological image 
of the patient in their study shows a hema-
toma, it is of small and therefore leads one 
to question how this can be responsible 
for such a midline shift. This suggests that 
something more must be involved, as was 
revealed at autopsy where a metastases was 
identified.
In a recent paper, Kruijff and Hoekstra 
(2012) state that the protein S-100B is prob-
ably the best biomarker for melanoma, 
having potential to identify high-risk stage 
III melanoma patients who may benefit 
from adjuvant systematic treatment. Since 
an effective (adjuvant) therapy for loco-
regional metastatic and disseminated mel-
anoma has only been recently introduced, 
the diagnostic of S-100B, they argue, is set 
to increase in the near future.
It therefore appears inappropriate to con-
sider differential levels of S-100B as indica-
tive of the evolution of CSH, as suggested 
by the paper’s title, since they can be more 
indicative of a melanoma and its metastasis.
A commentary on
Case report: extreme levels of serum 
S-100B in a patient with chronic subdural 
hematoma
by Persson M. E., Thelin E. P., and Bellander 
B. M. (2012) Front. Neurol. 3:170. doi: 10.3389/
fneur.2012.00170
We are surprised by the conclusions of a 
recent paper by Persson et al. (2012), “Case 
report: extreme levels of serum S-100B 
in a patient with chronic subdural hema-
toma,” which suggest that S-100B protein 
is an important marker for chronic sub-
dural hematoma (CSDH). In our opinion, 
and that of other authors, S-100B is a sig-
nificant marker of multiple neurological 
pathologies.
Chronic subdural hematoma is a rela-
tively common complication, especially 
among the elderly, where the incidence 
is estimated as 7.4/100,000. Two circum-
stances account for its high incidence 
among the elderly; the extensive brain atro-
phy often found in the elderly or alcoholics, 
and long-term use anticoagulant (Gelabert 
et al., 2001). CSDH in patients less than 
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